Valeant Pharmaceuticals To Acquire Synergetics USA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
BMO Capital Remains Bullish on Valeant Pharma (VRX) Following Announced Acquisition of Synergetics USA (SURG)
September 2, 2015 10:23 AM EDTBMO Capital reiterated an Outperform rating and $285.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's announced agreement to buy Synergetics USA (NASDAQ: SURG). Analyst Alex Arfaei said that although this is a small... More
